This session covers the changing epidemiology of chronic hepatitis B, including HCC risk stratification, vaccine-derived immunity trends, screening in high-burden settings, and refugee population data.

This session covers post-SVR risk stratification for HCC and liver-related outcomes in hepatitis C, plus novel diagnostics and public health strategies for testing and treatment in high-risk populations.

This session presents advances in HCC detection and prognostication, including deep learning imaging models, circulating biomarkers, and structured surveillance program outcomes.

This session reviews systemic and locoregional treatment strategies for advanced HCC, including network meta-analyses of combination therapies, AI-assisted tumor board support, and multidisciplinary decision-making outcomes.

This session reviews real-world and trial data on PBC therapeutics — including elafibranor, seladelpar, and linerixibat — alongside emerging biomarkers and digital tools for tracking pruritus and disease activity.

This session presents new data on predicting and managing acute-on-chronic liver failure (ACLF), covering updated diagnostic criteria, mortality risk in critically ill cirrhotic patients, and management of variceal bleeding and bloodstream infections in this population.

This session highlights the expanding role of advanced practice providers in hepatology, with a focus on MASLD screening, pharmacotherapy implementation, and care delivery innovation. Topics include APP-led lifestyle interventions, pharmacist- and nurse practitioner–driven treatment pathways, AI-assisted diagnostic tools, and the intersection of liver disease with menopause and hormonal therapy.

This session presents advances across the spectrum of alcohol-associated liver disease. Talks span novel risk-stratification and mortality-prediction tools (an explainable AI decision-support model, metabolic/quantitative-fibrosis histophenotyping, and decompensation in AH), evolving practices in early liver transplantation, and pre-transplant psychosocial evaluation. Complementary epidemiologic analyses examine sex differences in alcohol consumption that may inform alcohol risk assessment and public health policy.